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Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affecting multi-organs injury
and failure. The rapid, precision, and speciﬁcity prognosis by laboratory investigations could prevent active stage and
severity in the disease.
Aims: To systematically explore and investigate the candidate serum protein for development into the novel biomarker
for severity prognosis of SLE patients.
Methods: The proteins previously reported in abnormal level in serum/plasma of SLE patients since 2014e2020 were
comprehensive collected. Thereafter, these serum proteins that found in other diseases were excluded. The association with
molecules related to SLE severity of these candidate proteins were then predicted using bioinformatics STIRNG tool. The
level of altered protein, which had the strong interaction to the severity molecules in serum of SLE patients was validated by
Western blot, analyzed the correlation with anti-nuclear antigen (ANA) and performance of diagnosis, respectively.
Results: From 26 collected serum/plasma proteins, alpha-1-antitrypsin protein was found the abnormal level in only SLE
patients and strongly associated with severity molecules including C-reactive protein (CRP), complement C3, and C4.
Additionally, the validation of serum alpha-1-antitrypsin in SLE patients exhibited the higher level than healthy controls
and also had the positive correlation with ANA titer (r ¼ 0.710). Furthermore, the area under ROC curve for diagnostic
power of alpha-1-antitrypsin was 0.970 with 100% sensitivity and 90% speciﬁcity at cut-off 0.131/total serum protein.
Conclusions: The higher level of alpha-1-antitrypsin in serum samples of SLE patients indicated as the novel biomarker
for reliable and speciﬁc prognosis of disease severity.
Keywords: Biomarker, Protein, Serum, Prognosis, Systemic lupus erythematosus

1. Introduction

S

ystemic lupus erythematosus (SLE) is a highlyprevalent systemic autoimmune disease with
chronic inﬂammation that results in severe and lifethreatening illnesses. It can affect the global general
population of all ages and both sexes, especially
middle-aged (15e45 years old) women, who make up
approximately 90% of all patients [1,2]. SLE is characterized by the production of autoantibodies which
bind with nuclear (self) antigens via the pathogenic
mechanism of self-tolerance abnormality and the
activation of autoreactive lymphocytes. The binding
of autoantibodies to nuclear antigens can cause the

deposition of this immune complex in various organs
and tissues such as skin, brain, kidney, lung, etc.,
leading to multi-organ damage and failure [3e5].
Currently, the diagnosis and prognosis of severity in
SLE patients requires several laboratory investigations including the level of autoantibodies
(anti-dsDNA, anti-Sm, etc.), complement C3, C4 in
serum samples, and tissue biopsy for determination
of immune complex accumulation in organs [6,7].
Nevertheless, the accuracy of this molecule detection
requires a higher level in samples; patients have a
severe or advanced stage of disease, and these investigations could not differentiate SLE from other
diseases [8]. For reduction of this drawback, the new
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molecules in the serum/plasma of the patients,
especially proteins, shall be applied as an alternative
and/or supportive laboratory investigation for the
reliability of diagnosis/monitoring of disease severity
in organ tissues. Previously, studies of proteomic
analysis had reported the abnormality of various
serum/plasma protein levels in SLE patients, particularly the active stage, such as increased levels of
haptoglobin [9], ﬁbrinogen gamma chain [10], alpha1-antitrypsin [11,12], apolipoprotein B [11,12], or the
diminished level of apolipoprotein A-1 [9], histidinerich glycoprotein [10], clusterin [11], and albumin [12].
It is possible that several previous studies aimed to
explore the altered serum/plasma proteins for
serving as an alternative biomarker for the effective
diagnosis and/or severity monitoring of SLE [13].
Nevertheless, a large number of the previously reported proteins remained not to be estimated the
relationship with pathogenic mechanisms of SLE
disease and exactly validated the level in the patient’s
sample. In the present study, we gathered a
comprehensive collection of the proteomic data that
were previously published in medical and scientiﬁc
databases. Subsequently, the collected serum/plasma
proteins were chosen for further diagnosis/monitoring of SLE severity by the deﬁned criteria speciﬁc
to the patients and associated with various processes
of disease severity using a bioinformatics tool. The
serum level of the altered protein for a novel
biomarker in SLE patients was compared to healthy
controls by Western blot analysis, which determined
the correlation with a titer of anti-nuclear antibody
(ANA) testing, diagnostic performance with sensitivity and speciﬁcity values by statistical investigation.
Accordingly, the results of this study could establish
the ability of the altered serum protein in SLE patients
by systemic exploration and identiﬁcation based an
approach for development into a novel biomarker
that had speciﬁcity and relation with the change of
disease severity in multi-organ injury.

2. Methods
2.1. Subject selection and serum collection
The subjects in this study included ten participants who were SLE patients (age range: 20e45
years) according to sample size calculation (prevalence of the disease). These patients were diagnosed
according to the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 classiﬁcation criteria for SLE [14].
In addition, ten age- and sex-matched healthy individuals who had no autoimmune disease, liver
disease, or various systemic inﬂammatory diseases
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such as infection, diabetes mellitus, etc. were used
as the controls in this study. Blood samples from all
patients and controls were collected from the median cubital vein using an aseptic technique. The
serum from individual samples was separated by
centrifugation at 1,800g for 5 min, and then the level
of ANA was conﬁrmed using an immunoﬂuorescence test kit (Euroimmun AG, Lübeck, Germany)
according to the manufacturer's instructions.
Furthermore, serum samples were lyophilized until
completely dry using a lyophilizer (Labcon, CA,
USA) for performing further Western blot analysis.
2.2. Proteomics data retrieval
The data involved with serum/plasma proteins for
the disease diagnosis and prognosis of SLE patients
with the search terms including ‘serum protein in
SLE’ or ‘plasma protein in SLE’ were retrieved from
all published articles cited in PubMed and ScienceDirect database (2014e2020). All eligible serum/
plasma proteins collected by the previous proteomics reports were deﬁned as the expression alteration in only the SLE patients, not in healthy
controls and other diseases involved with the
change of protein level in serum/plasma, including
liver disease, and systemic inﬂammatory disease.
2.3. Proteineprotein interaction analysis
After the selection of proteomic data from previously published articles according to the aforementioned criteria, the altered serum/plasma proteins
were used to predict the association network with
the molecules related to the severity of SLE. This
included C-reactive protein (CRP), complement C1q,
C3, and C4 by Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING); version 11.0
(https://string-db.org/) with medium stringency/
conﬁdence level (score 0.400). This global network
analysis was carried out relative to gene ontology
(GO) terms based on the physical protein interactions from literature combined with the database of curated biological pathway knowledge.
2.4. Western blot analysis
The concentration of proteins derived from individual serum samples was initially measured by
Bradford’s method using a Coomassie Plus (Bradford) assay kit (Thermo Scientiﬁc Pierce, IL, USA).
An equal amount of protein in each sample (30 mg)
was resolved in 12% SDS-PAGE and then transferred onto a nitrocellulose membrane (Whatman,
Dassel, Germany) using a semidry transfer
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apparatus (Bio-Rad Laboratories, CA, USA) at
85 mA for 1 h. The membrane was stained with
Ponceau S dye (SigmaeAldrich, MO, USA) to verify
equal protein loading and to serve as the loading
control for subsequent quantitative intensity analysis. Subsequently, the membrane was destained
with phosphate buffer saline (PBS), and non-speciﬁc
bindings were blocked with 5% skim milk in PBS at
25  C for 1 h. The membrane was then incubated
with rabbit monoclonal anti-alpha-1 antitrypsin
(Abcam, Cambridge, UK) diluted 1:2000 in 1% skim
milk/PBS at 4  C, overnight. After washing with
PBS, the membrane was incubated with goat-antirabbit immunoglobulin G (IgG) H&L conjugated
with horseradish peroxidase (HRP) (Abcam, Cambridge, UK) diluted 1:10,000 in 1% skim milk/PBS at
25  C for 1 h. After washing with PBS, the bands of
immune reactive protein were visualized by Clarity
western enhanced chemiluminescence (ECL) substrate (Bio-Rad Laboratories, CA, USA) and autoradiography. The data of band intensity in each
sample was obtained using ImageJ (National Institutes of Health (NIH), MD, USA).
2.5. Ethical issues
All patients provided written informed consent
prior to participation. The study was approved by
the UPHEC, Thailand (approval no. 2/143/62) in
concordance with international guidelines including
the Declaration of Helsinki, the Belmont Report, and
ICH Good Clinical Practice.
2.6. Statistical analysis
The quantitative data were presented as
mean ± standard deviation (SD). Comparison between the two groups and the relationship between
two parameters were examined by ManneWhitney
U test and Spearman correlation following linear
regression, respectively. Diagnostic performance
was analyzed by the area-under-the-curve (AUC) of
the receiver operating characteristic (ROC), with a
p-value  of 0.05 considered statistically signiﬁcant.
Statistical analyses were performed using SPSS
(Version 25; IBM, NY, USA) and GraphPad Prism
(Version 8; GraphPad Software, CA, USA).

3. Results
3.1. Systematic collection of proteomic data in SLE
serum/plasma
All of the serum/plasma proteins that were altered
in SLE patients were retrieved from previous
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proteomics studies using a literature search with the
term ‘serum/plasma proteins in SLE’ from the PubMed
and ScienceDirect databases since 2014 to 2020.
Previous data in SLE patients based on statistical
fold-change compared to healthy controls exhibited
elevated 19 serum/plasma proteins. These included
haptoglobin (HP), syndecan-1 (SDC-1), insulin-like
growth factor binding protein II (IGFBP2), tumor
necrosis factor receptor type II (TNFR2), tyrosineprotein kinase receptor UFO (Axl ), ﬁbrinogen
gamma chain (FGG), protein S100-A9 (S100A9),
marginal zone B and B1 cell-speciﬁc protein (MZB1),
alpha-1-acid glycoprotein 1 (ORM1), alpha-1-acid
glycoprotein 2 (ORM2), alpha-1-antitrypsin (SERPINA1), alpha-2-macroglobulin (A2M ), apolipoprotein B (APOB), ceruloplasmin (CP), complement
factor H (CFH ), hemoglobin subunit alpha-1 (HBA1), hemoglobin subunit beta (HBB), retinol-binding
protein (RBP4), and serotransferin (TF ). In contrast,
7 serum/plasma proteins were found to reduce
including glutathione S-transferase kappa 1 isoform
c (GSTK1), apolipoprotein A-1 (APOA1), histidinerich glycoprotein (HRG), hemopexin (HPX ), albumin (ALB), clusterin (CLU ), and ﬁbrinogen beta
chain (FGB) (Table 1).
3.2. Selection of serum/plasma proteins for
candidate biomarkers
The collected 26 serum/plasma proteins of SLE
patients were subsequently selected to serve as the
candidate biomarkers for speciﬁc prognosis of
severity by following deﬁned criteria, including only
the encounter in SLE patients (active and/or inactive), not in other systemic autoimmune diseases
such as rheumatoid arthritis, etc., or systemic inﬂammatory diseases such as diabetes mellitus, etc.,
and liver diseases. The proteins that had the altered
level in serum/plasma of SLE patients with the
contrast of other related diseases as aforementioned
were also selected for further investigation. For
example, alpha-1-antitrypsin (SERPINA1) was
selected because there was an increased level in SLE
patients, but was found to diminish in other systemic autoimmune diseases and liver diseases. The
results demonstrated that tumor necrosis factor receptor type II (TNFR2), tyrosine-protein kinase receptor UFO (Axl ), protein S100-A9 (S100A9), alpha1-acid glycoprotein 2 (ORM2), alpha-1-antitrypsin
(SERPINA1), hemopexin (HPX ), ﬁbrinogen beta
chain (FGB), and serotransferrin (TF ) had properties
based on the aforementioned criteria (Fig. 1). This
suggests that these proteins may serve as speciﬁc
candidate biomarkers for the prognosis of disease
severity in SLE patients.
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No.

Protein name

Gene name

Reference

Level (Fold change
to healthy control)

Source

1
2
3
4
5
6
7
8
9
10
11

Glutathione S-transferase kappa 1 isoform c
Apolipoprotein A-1
Haptoglobin
Syndecan-1
Insulin-like growth factor binding protein II
Tumor necrosis factor receptor type II
Tyrosine-protein kinase receptor UFO
Fibrinogen gamma chain
Histidine-rich glycoprotein
Protein S100-A9
Marginal zone B and B1 cell-speciﬁc protein

GSTK1
APOA1
HP
SDC-1
IGFBP2
TNFR2
Axl
FGG
HRG
S100A9
MZB1

Wang L et al., 2012 [15]
Kazemipour N et al., 2015 [9]

Decreased (0.5)
Decreased (0.8)
Increased (1.3)
Increased (1.9)
Increased (3.1)
Increased (3.9)
Increased (1.8)
Increased (6.2)
Decreased (1.0)
Increased (1.0)
Increased (2.5)

12
13
14
15

Albumin
Alpha-1-acid glycoprotein 1
Alpha-1-acid glycoprotein 2
Alpha-1-antitrypsin

ALB
ORM1
ORM2
SERPINA1

16

Alpha-2-macroglobulin

A2M

Increased (3.812)

17
18
19

Apolipoprotein B
Ceruloplasmin
Clusterin

APOB
CP
CLU

Increased (3.212e411)
Increased (2.912e3.611)
Decreased (0.411)

20
21
22
23
24
25
26

Complement factor H
Fibrinogen beta chain
Hemoglobin subunit alpha-1
Hemoglobin subunit beta
Hemopexin
Retinol-binding protein
Serotransferrin

CFH
FGB
HBA-1
HBB
HPX
RBP4
TF

Increased (3.612)
Decreased (0.612)
Increased (5.312)
Increased (2.611e3.812)
Decreased (0.211)
Increased (4.112)
Increased (2.311)

Serum, PBMC
Serum
Serum, Urine
Serum
Serum
Serum, PBMC
Serum
Serum
Serum
Serum, PBMC
Serum, B-cell,
Lymph node biopsy
Serum
Serum
Serum
Serum, Urine,
Renal biopsy
Serum, Urine,
Renal biopsy
Serum
Serum, Urine
Serum, Urine,
Renal biopsy
Serum
Serum
Serum
Serum
Serum
Serum
Serum

Kim KJ et al., 2015 [16]
Mok CC et al., 2016 [17]

Zhong L et al., 2017 [10]

Miyagawa-Hayashino A et al., 2018 [18]
Madda R et al., 2018 [11] and 2019 [12]

Decreased (0.812)
Increased (2.911)
Increased (2.311)
Increased (3.012 - 3.211)
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Table 1. List of serum proteins in SLE patients retrieved from all published articles cited in PubMed and ScienceDirect database since 2014 to 2020.
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Fig. 1. List of the candidate proteins in serum/plasma of SLE patients that were found the abnormal level in only SLE (active and/or inactive), not in
other systemic autoimmune disease, systemic inﬂammatory disease, and liver disease (dot box) from 26 collected proteins in the published articles cited
in PubMed and ScienceDirect database since 2014 to 2020.

3.3. Association of the candidate serum proteins
with molecules related to SLE severity
Tumor necrosis factor receptor type II (TNFR2),
tyrosine-protein kinase receptor UFO (Axl ), protein
S100-A9 (S100A9), alpha-1-acid glycoprotein 2
(ORM2), alpha-1-antitrypsin (SERPINA1), hemopexin
(HPX ), ﬁbrinogen beta chain (FGB), and serotransferrin (TF ) were reported to vary in active SLE
patients. However, there was no change of serum/
plasma expression in other systemic autoimmune
diseases, systemic inﬂammatory disease, or liver
disease, which were then subjected to the protein
network analysis STRING bioinformatics tool to
investigate the association between these candidate
biomarkers with CRP, complement C1q, C3, and C4.

The integrative proteome network created by the
STRING tool showed that tumor necrosis factor receptor type II (TNFR2), alpha-1-antitrypsin (SERPINA1), hemopexin (HPX ), and ﬁbrinogen beta chain
(FGB) strongly interacted with CRP (Fig. 2A), alpha1-acid glycoprotein 2 (ORM2), alpha-1-antitrypsin
(SERPINA1), and serotransferrin (TF ), interacted
strongly with complement C3 (Fig. 2B), while, alpha1-antitrypsin (SERPINA1), and serotransferrin (TF)
interacted strongly with complement C4 (Fig. 2C).
From the results, alpha-1-antitrypsin (SERPINA1)
was shown to relate with all inﬂammatory molecules
in the current study, including CRP, complement C3,
and C4 (Fig. 3), indicating that this serum/plasma
protein had the closest association with the disease
severity of SLE.
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Fig. 3. Diagram illustrating the association of 8 candidate proteins in
serum/plasma of SLE patients with the severity molecules in this study
including CRP, complement C3, and C4 (SERPINA1), both of C3 and
C4 (TF), only CRP (TNFRSF1B, FGB, and HPX), only C3 (ORM2), and
also had not associated with all of the severity molecules (Axl and
S100A9), respectively after predicting analysis of the interaction by
bioinformatics tool.

was adjusted and then incubated with a monoclonal
antibody speciﬁc to alpha-1-antitrypsin for validation of alpha-1-antitrypsin level in serum sample of
the patients compared to controls. The serum level
of
alpha-1-antitrypsin
in
SLE
patients
(233.02 ± 14.32 mg/dl) was shown to be signiﬁcantly
higher than in healthy controls (107.54 ± 7.38 mg/dl)
(p < 0.05) (Fig. 4).
3.5. Correlation between alpha-1-antitrypsin level
and ANA titer in serum sample of SLE patients

Fig. 2. Bioinformatics analysis of proteineprotein interaction between 8
candidate serum proteins in SLE patients with molecules related to
disease severity consisting CRP (A), complement C3 (B), and C4 (C) by
STRING tool, version 11.0 (http://string.embl.de/). Each interacting line
color represented the interaction evidences contained curate database
(blue), text mining (yellow), co-expression (black), and experimental
determined (pink).

3.4. Validating the level of alpha-1-antitrypsin in
the serum of SLE patients
The amount of total protein from individual
serum samples in SLE patients and healthy controls

ANA is currently indicated as a marker for laboratory diagnosis and also the prognosis of SLE
severity. Therefore, ANA titer was applied to
examine the correlation with the level of alpha-1antitrypsin level in serum samples of SLE patients.
The analysis of statistic correlation revealed that the
serum level of alpha-1-antitrypsin was positively
related to ANA positive titer (r ¼ 0.710, p < 0.05) in
SLE patients (Fig. 5).
3.6. Diagnostic power of serum alpha-1-antitrypsin
level
The diagnostic power of alpha-1-antitrypsin in
serum samples was evaluated by ROC analysis. The
area under the ROC curve after comparison between SLE patients and healthy controls was found
at 0.970 (95% conﬁdence interval; CI ¼ 0.907e1.000,
p < 0.05). For distinguishing serum alpha-1-antitrypsin level in SLE patients from healthy controls,
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Fig. 4. Level of serum alpha-1-antitrypsin (SERPINA1) in SLE patients (N ¼ 10) was validated and compared to healthy controls (N ¼ 10) by
Western blot analysis. (A) An equal amount of protein extracted from individual sample (30 mg) were subjected to SDS-PAGE and followed by
monoclonal antibody speciﬁc to alpha-1-antitrypsin (SERPINA1). (B) Band intensity of alpha-1-antitrypsin (SERPINA1) was measured using ImageJ
software and normalized with total protein in each sample of SLE patients and healthy controls. The data in each bar was obtained from 10 independent participants and represented as mean ± SD. * p < 0.05 vs. controls.

the optimal cut-point of this protein was estimated
by identiﬁcation of value, which yielded the highest
sensitivity and speciﬁcity. The cut-point of serum
alpha-1-antitrypsin as 0.131/total serum protein was
found to yield a sensitivity of 100% and speciﬁcity of
90% (Fig. 6).

4. Discussion
Literature searches of published articles concerning proteomics study from PubMed and ScienceDirect between 2014 and 2020 [9e12,15e18] were
applied to comprehensively collect various serum/
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Fig. 5. The correlation analysis of serum alpha-1-antitrypsin (SERPINA1) level with ANA positive titer from 10 independent participants
of SLE patients.

plasma proteins in SLE patients. The data in these
published articles indicated 26 proteins from SLE
patients had an abnormal (increased or decreased)
level compared to healthy controls (Table 1). In
addition, the abnormal level of 8 from 26 collected
serum/plasma proteins was suggested as a candidate serum/plasma biomarker for speciﬁc prognosis
of SLE severity because these proteins had only
been encountered in SLE patients, especially the
active stage of the disease, or found a contrast level
with other diseases involved with 1) the pathogenesis of SLE, including systemic autoimmune diseases and systemic inﬂammatory diseases, and 2)

Fig. 6. ROC curve in the evaluating diagnostic ability of serum alpha-1antitrypsin (SERPINA1) in SLE patients (N ¼ 10) and healthy controls
(N ¼ 10).
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the abnormal production of circulatory proteins in
liver diseases (Fig. 1). The candidate serum/plasma
proteins, which were found in only SLE patients,
consisted of tumor necrosis factor receptor type II
(TNFR2), tyrosine-protein kinase receptor UFO
(Axl ), hemopexin (HPX ), ﬁbrinogen beta chain
(FGB), and serotransferrin (TF ) (Fig. 1). Although the
level of protein S100-A9 (S100A9), alpha-1-acid
glycoprotein 2 (ORM2), alpha-1-antitrypsin (SERPINA1) was altered in various diseases other than
SLE, these proteins were selected for the candidate
biomarker because of the establishing contrast level
in serum/plasma between SLE patients and other
related diseases, i.e., the level of alpha-1-antitrypsin
(SERPINA1) was found to increase in SLE, but
diminish in other systemic autoimmune diseases
and liver diseases.
Acute-phase protein CRP, complement C3 and C4
have been reported as crucial molecules related to
disease severity in multi-organ damage of SLE patients via an inﬂammatory process and immune
attack to the organ tissues, respectively [19,20].
Moreover, these molecules have been found in the
circulatory system and could monitor disease
severity progression in patients [6,7]. The molecules
of CRP, complement C3 and C4, were applied to
analyze the association with 8 candidate proteins in
serum/plasma speciﬁc to SLE patients from the selection in the aforementioned criteria. Bioinformatics has recently been established as an important
tool for visualizing, analyzing and retrieving the
structure, kinetic and interaction of proteins from a
large number of proteomic data sets. In addition, the
identiﬁcation of proteineprotein interaction could
provide understanding and insight into the cellular
dynamics and functions involved in the pathogenesis of the disease [21]. Bioinformatics tool was
applied to analyze the proteineprotein interaction
of the candidate biomarker with severity molecules
in the circulatory system of SLE. STRING is a useful
database and online resource (http://string-db.org)
for the prediction of proteineprotein association
encoded by the known gene from many sources
comprising experimental data, computational
analyzing, and text collection. The STRING tool can
generate an association among proteins based on
raw data repositories as well as formalize pathways
retrieved from protein databases and literature
searches. The conﬁdence of interaction score in the
network was also supported to achieve a strong
proteineprotein interaction [22,23]. The protein
network analysis revealed that alpha-1-antitrypsin
strongly interacted with CRP, complement C3 and
C4 with curate database, text mining, and/or coexpression (Figs. 2 and 3). Nevertheless, the
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remaining candidate serum proteins consisting of
serotransferrin, tumor necrosis factor receptor type
II, ﬁbrinogen beta chain, hemopexin, alpha-1-acid
glycoprotein 2, tyrosine-protein kinase receptor
UFO, and protein S100-A9 were found to not be
associated with all of the circulatory molecules
related to SLE severity in this study (CRP, complement C3 and C4) (Fig. 3). Therefore, the bioinformatics data implied alpha-1-antitrypsin was the
most altered serum biomarker for the prognosis of
disease severity in SLE patients.
Alpha-1-antitrypsin is a human alpha globulin
glycoprotein encoded by the SERPINA1 gene and
belonging to the serpin superfamily (inhibitor of
serine protease). It is mostly produced by hepatocytes and by other cells to a lesser extent, such as
macrophages/monocytes, neutrophil, pancreas,
enterocytes, and some cancer cells [24,25]. In addition, alpha-1-antitrypsin can be secreted into the
bloodstream with a half-life of 4e5 days. It has been
found to be the most abundant serine protease inhibitor in the human circulatory system [26,27].
Because alpha-1-antitrypsin can inhibit serine protease, neutrophil elastase, and other enzymes in
inﬂammatory cells, the biological roles of this protein are intimately involved with the inﬂammatory
process. Moreover, alpha-1-antitrypsin could regulate the pathways of ﬁbrinolysis, complement and
coagulation [23,24], and its concentration in the
bloodstream was also rapidly raised during inﬂammation to respond to the process [24,28], suggesting
an acute-phase protein. Based on supporting data
from previous and present studies, alpha-1-antitrypsin in SLE patients was then validated the
serum level by Western blot analysis. The results
demonstrated that serum alpha-1-antitrypsin was
increased in SLE patients as compared to healthy
controls (Fig. 4). Our ﬁndings were consistent with
previous data that showed an increased plasma
concentration of alpha-1-antitrypsin in SLE patients
with severe cardiovascular manifestation than
without- and healthy controls [29]. Moreover,
various forms of circulating alpha-1-antitrypsin
have exhibited the biological role involved with the
inﬂammatory process, immune response and also
found in patients. For example, the cleaved form
was able to activate neutrophil for immunity
enhancement, while S-nitrosylated form could
induce pro-inﬂammatory cytokines and inducible
nitric oxide synthase (iNOS) secreted from activated
macrophages, oxidized and alpha-1-antitrypsin/
immunoglobulin complex form was shown in patients with inﬂammatory diseases and systemic
autoimmune disease, respectively [30,31]. Moreover,
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the production of alpha-1-antitrypsin in various
cells such as hepatocytes could be upregulated by
cytokines, especially interleukin-6 (IL-6) secreted
from inﬂammatory cells [32]. IL-6 from monocytes
was found to signiﬁcantly alter the glycosylation for
the production of the glycosylated form of alpha-1antitrypsin related to several inﬂammatory conditions and diseases [33]. Additionally, the severity of
SLE in the active stage was also demonstrated to be
associated with the dysregulation of IL-6 inﬂammatory cytokine secretion in patients [34]. Hence,
the level of alpha-1-antitrypsin in the serum sample
had profound relevance to the pathogenic mechanism of disease severity in SLE patients, especially
the inﬂammatory process and possibly through IL-6
induction, which should be investigated in further
study.
The positive titer of ANA over a laboratory
reference range is established as one of the
important criteria for diagnosis and classiﬁcation of
SLE according to the 2019 EULAR/ACR criteria
[14]. Additionally, immunoﬂuorescence ANA
testing has been indicated as the gold standard of
laboratory investigation for SLE diagnosis, severity
prognosis, and therapeutic monitoring [35]. The
level of serum alpha-1-antitrypsin in SLE patients
was applied to analyze the statistic correlation with
the aforementioned gold standard method. The
results exhibited the positive correlation between
alpha-1-antitrypsin level to the ANA positive titer
with high linearity (r ¼ 0.710) (Fig. 5). Moreover, the
level of alpha-1-antitrypsin with cut-point as 0.131/
total serum protein was found to have a high
sensitivity (100%) and speciﬁcity (90%) in the
discrimination of SLE patients from healthy controls by ROC curve analysis (Fig. 6). It is possible
that alpha-1-antitrypsin could serve as a novel
serum biomarker for a rapid, speciﬁc, and reliable
prognostic tool of disease severity associated with
organ damage in SLE patients via the process of
complementary and inﬂammatory activations.
Previous study also demonstrated that alpha-1antitrypsin was markedly present in the urine
samples of SLE patients with active renal conditions for serving as a potential biomarker of lupus
nephritis activity, which possibly had involvement
with proteinuria in the patients [36]. Furthermore,
the therapeutic potential of alpha-1-antitrypsin was
recently evaluated and revealed a promising result
with a safety proﬁle on various autoimmune diseases such as type 1 diabetes, rheumatoid arthritis,
and systemic lupus erythematosus, which is
possibly caused by an anti-inﬂammatory effect of
the protein [37].
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After the formation of an immune complex between autoantibodies with soluble nuclear antigen,
this complex can deposit multi-organ tissues and
also activate the classical pathway of the complementary system. The activation of this pathway ultimately results in the formation of a membrane
attack complex (MAC) by the assembly of complement C5b, C6, C7, C8, and C9 for the lysis of target
cells [20]. Additionally, the complement cascade can
produce complement C5a, which is a potent
chemotaxis factor for inducing the migration of inﬂammatory cells consisting of neutrophils, monocytes, and other granulocytes into damaged organ
tissues. Furthermore, these inﬂammatory cells are
subsequently stimulated at the site of inﬂammation
for cellecell adhesion, production and secretion of
various inﬂammatory mediators such as acutephase proteins, and pro-inﬂammatory cytokines,
resulting in further systemic organ injury and
eventual failure [20,38]. Recently, the disease
severity in multi-organ tissues of SLE patients was
monitored by the level of CRP as an acute-phase
protein, complement, especially C3 and C4 in
serum/plasma, and also the ﬁnding of immune
complex accumulated in organs [6,7]. These current
laboratory investigations revealed several defects
including the low sensitivity of detection and speciﬁcity to the patients [39]. The present study had
limitations for obtaining a larger spectrum of SLE
patients with various levels of IL-6 cytokine and
stages of severity consisting of the non-active stage,
active stage with nephritis, arthritis, or photosensitivity, etc. because there have been conﬁned cases of
SLE patients in Thailand [2]. These clinical stages of
SLE severity were previously found to be associated
with the different phenotypes of alpha-1 antitrypsin
[37], suggesting that the validation of alpha-1 antitrypsin level in SLE’ serum should further consider
the clinical association and also the IL-6 level of the
patients. From our results, an increased level of
serum alpha-1-antitrypsin speciﬁc in SLE patients
associated with the pathogenic mechanisms of
severity might indicate the need for an alternative
laboratory investigation concerning the signiﬁcance
of prognosis and monitoring of disease. Furthermore, the increased level of serum alpha-1 antitrypsin in SLE patients might provide beneﬁcial
information for the potential management of disease severity as well as both prevention and treatment, which is the translational medical
development of SLE. This data can be also used as a
guideline for functional studies to better understand
the pathogenic mechanisms in the disease progression of SLE leading to multi-organ injury.
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5. Conclusion
The present study demonstrated that alpha-1antitrypsin is a serum/plasma protein that specifically increased levels in SLE patients and dramatically showed the association with all of the severity
molecules containing CRP, complement C3, and C4
by a systematic review of proteome data-based
approach, and integrative bioinformatics analysis,
respectively. In addition, the analysis of Western
blot and statistic correlation showed a higher level
of this protein in SLE patients compared to healthy
controls as well as a strong correlation with the ANA
titer in another laboratory diagnosis. Furthermore,
the cut-point of serum alpha-1-antitrypsin at 0.131/
total serum protein could discriminate patients from
controls with high sensitivity and speciﬁcity. Taken
together, the level of alpha-1-antitrypsin has the
potential to be applied as a novel serum biomarker
for further supporting the prognosis and monitoring
of the change in SLE severity speciﬁc to patients.
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